RESEARCH TRIANGLE PARK, N.C. – May 4, 2026
Opus Genetics Inc. has announced that its investigational gene therapy OPGx-LCA5 has been accepted into the U.S. Food and Drug Administration Rare Disease Evidence Principles (RDEP) program, a strategic regulatory initiative designed to accelerate development of treatments for ultra-rare genetic diseases. This milestone strengthens the company’s pathway toward potential approval of a first-in-class therapy for Leber congenital amaurosis type 5 (LCA5), a severe inherited retinal disorder that leads to early-onset blindness and currently has no approved targeted treatment options, highlighting a major opportunity in gene therapy innovation within Bio-Pharma.
RDEP Program Strengthens Regulatory Pathway
The RDEP program is a newly introduced FDA framework aimed at addressing the unique challenges of developing therapies for diseases affecting fewer than 1,000 patients in the United States, enabling early and continuous collaboration between regulators and sponsors to streamline development. Through this program, Opus Genetics Inc. will receive guidance on clinical trial design, regulatory strategy, and innovative evidence generation approaches, which are critical when working with small patient populations and limited datasets.
Importantly, the program allows for flexible approval pathways, including the potential use of a single well-controlled clinical study supported by confirmatory evidence, significantly reducing development timelines and regulatory uncertainty. This positions OPGx-LCA5 for a more efficient transition into pivotal Phase 3 trials, while aligning expectations with the FDA early in the process.
OPGx-LCA5 Shows Strong Clinical Potential
Advertisement
OPGx-LCA5 is an AAV8-based gene therapy designed to deliver a functional copy of the LCA5 gene, which encodes the lebercilin protein, directly to retinal cells. The therapy targets Leber congenital amaurosis type 5, a rare genetic condition characterized by progressive degeneration of retinal structure and function, leading to severe visual impairment in early childhood.
Early clinical data from Phase 1/2 trials conducted at the University of Pennsylvania demonstrate meaningful improvements in cone-mediated vision, with pediatric patients showing significant gains in visual function, while adult patients exhibited durable improvements in cone sensitivity lasting up to 18 months. Equally important, the therapy has shown a favorable safety profile, with no serious ocular adverse events or dose-limiting toxicities, strengthening confidence in its long-term viability. These results indicate that gene augmentation strategies can effectively restore visual function, making OPGx-LCA5 a promising candidate in retinal gene therapy development.
Expanding Leadership in Genetic Eye Disease Treatments
Opus Genetics Inc. is positioning itself as a key player in the inherited retinal disease (IRD) treatment landscape, with a pipeline of AAV-based gene therapies targeting multiple genetic mutations, including BEST1, RDH12, MERTK, RHO, CNGB1, and NMNAT1. The acceptance of OPGx-LCA5 into the RDEP program adds to its existing regulatory designations, including Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) status, collectively reinforcing the scientific and regulatory strength of the program.
Beyond gene therapy, the company is also advancing small-molecule ophthalmic treatments, further diversifying its portfolio. This milestone reflects a broader industry trend where precision gene therapies are emerging as one-time, disease-modifying treatments, capable of addressing the root genetic cause of previously untreatable conditions, signaling a shift toward curative approaches in Bio-Pharma innovation.
Source: Opus Genetics press release
